화학공학소재연구정보센터
Journal of Industrial and Engineering Chemistry, Vol.73, 182-191, May, 2019
Conjugation of prostate cancer-specific aptamers to polyethylene glycol-grafted polyethylenimine for enhanced gene delivery to prostate cancer cells
E-mail:
Prostate cancer is one of the most frequently diagnosed cancers. In this study, a prostate cancer-specific aptamer, Wy5a, was conjugated to polyethylenimine (PEI) with a polyethylene glycol (PEG) linker for prostate cancer-specific gene delivery. PEI-PEG-AS1411 was synthesized as a non-specific control. PEI-PEG-Wy5a formed complexes with plasmid DNA in a spherical form with a diameter of 70 nm and a positive surface-charge. In transfection assays, PEI-PEG-Wy5a had higher gene delivery efficiency to PC-3 prostate cancer cells than did PEI-PEG or PEI-PEG-AS1411, but not in other types of cells. The results suggest that PEI-PEG-Wy5a may be useful for prostate cancer-specific gene delivery.
  1. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, J. Huang, Prostate, 71, 1668 (2011)
  2. Cooperberg MR, Park S, Carroll PR, Oncology, 18, 1239 (2004)
  3. Siegel R, Ma J, Zou Z, Jemal A, Cancer CA, J. Clin., 64, 9 (2014)
  4. Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S, Biomaterials, 31, 4592 (2010)
  5. Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, Nat. Rev. Cancer, 17, 286 (2017)
  6. El-Aneed A, J. Control. Release, 94, 1 (2004)
  7. Chae SY, Kim HJ, Lee MS, Jang YL, Lee Y, Lee SH, Lee K, Kim SH, Kim HT, Chi SC, Park TG, Jeong JH, Macromol. Biosci., 11, 1169 (2011)
  8. Jeon P, Choi M, Oh J, Lee M, Macromol. Biosci., 15, 1021 (2015)
  9. Xiao S, Liu Z, Deng R, Li C, Fu S, Chen G, Zhang X, Ke F, Ke S, Yu X, J. Control. Release, 258, 130 (2017)
  10. Kim HA, Park JH, Yi N, Lee M, Mol. Pharm., 11, 938 (2014)
  11. Pack DW, Hoffman AS, Pun S, Stayton PS, Nat. Rev. Drug Discov., 4, 581 (2005)
  12. Mangraviti A, Tzeng SY, Kozielski KL, Wang Y, Jin Y, Gullotti D, Pedone M, Buaron N, Liu A, Wilson DR, A.C.S Nano, 9, 1236 (2015)
  13. Lv H, Zhang S, Wang B, Cui S, Yan J, J. Control. Release, 114, 100 (2006)
  14. Wang Y, Luo Y, Bing T, Chen Z, Lu M, Zhang N, Shangguan D, PLoS. One, 9, e10024 (2014)
  15. Zhou J, Rossi J, Nat. Rev. Drug Discov., 16, 181 (2017)
  16. Chen K, Liu B, Yu B, Zhong W, Lu Y, Zhang J, Liao J, Liu J, Pu Y, Qiu L, Nanomed. Nanobiotech, 9, e1438 (2017)
  17. Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z, Biomaterials, 35, 3840 (2014)
  18. Li X, Yu Y, Ji Q, Qiu L, Nanomed. Nanotech. Biol. Med., 11, 175 (2015)
  19. Reyes-Reyes E, Salipur FR, Shams M, Forsthefel MK, Bates PJ, Mol. Oncol., 9, 1392 (2015)
  20. Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ, Cancer Res., 68, 2358 (2008)
  21. Maier KE, Levy M, Mol. Ther. Method. Clin. Dev., 3 (2016)
  22. Duan M, Long Y, Yang C, Wu X, Sun Y, Li J, Hu X, Lin W, Han D, Zhao Y, Oncotarget, 7, 36436 (2016)
  23. Guan XW, Guo ZP, Wang TH, Lin L, Chen J, Tian HY, Chen XS, Biomacromolecules, 18(4), 1342 (2017)
  24. Luong D, Kesharwani P, Deshmukh R, Amin MCIM, Gupta U, Greish K, Iyer AK, Acta Biomater., 43, 14 (2016)
  25. Wang H, Zhao X, Guo C, Ren D, Zhao Y, Xiao W, Jiao W, PLoS One, 10, e01391 (2015)
  26. Lemkine GF, Goula D, Becker N, Paleari L, Levi G, Demeneix BA, J. Drug Target., 7, 305 (1999)
  27. Godbey W, Wu KK, Mikos AG, J. Control. Release, 60, 149 (1999)
  28. Park TG, Jeong JH, Kim SW, Adv. Drug Deliv. Rev., 58, 467 (2006)
  29. Kim YH, Park JH, Lee M, Kim YH, Park TG, Kim SW, J. Control. Release, 103, 209 (2005)
  30. Taranejoo S, Liu J, Verma P, Hourigan K, J. Appl. Pol. Sci., 132 (2015).
  31. Fischer D, Bieber T, Li Y, Elsasser HP, Kissel T, Pharm. Res., 16, 1273 (1999)